We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Comen Medical

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Jan 2022 - 27 Jan 2022

Thoracic Bioimpedance System Monitors Respiratory Motion

By HospiMedica International staff writers
Posted on 10 May 2021
Print article
Image: The ExSpiron2Xi respiration monitor (Photo courtesy of Respiratory Motion)
Image: The ExSpiron2Xi respiration monitor (Photo courtesy of Respiratory Motion)
A new digital breathing volume monitor helps assess respiratory function and provide early warning of impending collapse.

The Respiratory Motion (Watertown, MA, USA) ExSpiron 2Xi Respiratory Monitor System is a non‐invasive device designed to monitor breathing in patients of at least one year of age. The device contains a bioimpedance measurement system and a tablet PC housed within a single enclosure. The tablet uses a graphical user interface (GUI) for user input from the touch screen through a virtual keyboard and mouse, and presents respiratory tracing, as well as approximate scalar values and trends for minute ventilation (MV), tidal volume (TV), and respiratory rate (RR).

A reusable cable connects the ExSpiron 2Xi Monitor to a stabilized high frequency current generator and a single patient use electrode PadSet that is placed on the torso to deliver current to the patient’s skin. The same electrode PadSet records returning the impedance measurements, and an adaptive firmware circuit then conditions the voltage signal and converts it to digital form. Finally, a proprietary built-in software algorithm calculates respiratory parameters based on a non‐linear, regressive model trained data set.

“The Proven Respiratory Sentry has a new formula, and I am proud of announcing the launch of our ExSpiron2Xi,” said Laura Piccinini, CEO of Respiratory Motion. “Unique. Accurate. Confidence. The new digital platform of enhanced monitoring falls in line with Respiratory Motion's commitment to rapidly innovate leading-edge products and services that establish accurate and safe new products. Inspired Innovation is the fil rouge in Respiratory Motion's culture of meeting customer needs.”

Respiratory compromise increases patient mortality rates by over 30%, and hospital and ICU stays by almost 50% following post-operative respiratory failure, and is the largest single-source of avoidable in-patient days and the third most common patient safety event. By measuring MV, the amount of air moved through the lungs in one minute a an indication of the patient’s respiratory status can guide pain management, assess respiratory sufficiency, identify risk, and to individualize patient care pathways. MV can also replace End-Tidal CO2 for monitoring opioid induced respiratory depression.

Related Links:
Respiratory Motion

Print article



view channel

J&J Medical Devices Companies Partners with Microsoft to Further Enable its Digital Surgery Solutions

The Johnson & Johnson Medical Devices Companies (JJMDC; New Brunswick, NJ, USA) will collaborate with Microsoft (Redmond, Wash., USA) to further enable and expand JJMDC’s secure and compliant digital... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.